万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://www.journals.elsevier.com/ebiomedicine
https://www.thelancet.com/journals/ebiom/home
3、投稿网址：https://www.editorialmanager.com/EBIOM
4、期刊刊期：月刊，一年出版十二期。
2021年5月7日星期五
投稿须知【官网信息】
Information for Authors
EBioMedicine is a gold open-access journal dedicated to publishing original research that illuminates, or aims to modify, disease pathways and mechanisms—with the goal of advancing our knowledge in any biomedical discipline with relevance to human health. We publish papers investigating the basic determinants of human health and disease, the discovery and characterisation of new therapeutic targets and treatments, and the identification of biomarkers and diagnostic tools which may help researchers and clinicians better understand and monitor disease. EBioMedicine covers the whole spectrum of biomedical research, from in vitro and preclinical studies with clear human relevance, through to proof-of-concept studies and clinical trials. The journal will also publish relevant reviews, commentaries and opinion pieces. We aspire to catalyse dialogue and collaboration between basic scientists, clinical researchers and healthcare professionals, enhance the accessibility and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.
Manuscript preparation must adhere to relevant reporting standards on EQUATOR network website (Enhancing the Quality and Transparency of Health Research). Further details on the different sections of EBioMedicine, and how to submit to the journal, are provided below. If you require further clarification, the journal’s editorial staff will be pleased to help (ebiom@lancet.com).
Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. The Lancet journals are signatories of the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors (ICMJE Recommendations), and to the Committee on Publication Ethics (COPE) code of conduct for editors. We follow COPE’s guidelines.
How to submit your paper
Manuscript submission
Manuscript submission to all Lancet journals is free. Payment of article processing fees is made after acceptance (see Article Processing Charges section). Manuscripts should be submitted online via the EBioMedicine’s online submission and peer review website (known as EM) at www.editorialmanager.com/ebiom
• Simply log on to EM and follow the on-screen instructions for all submissions
• If you have not used EM before, you will need to register first. In EM, the corresponding author is the person who enters the manuscript details and uploads the submission files
• Inclusion of illustrations (eg, photographs, graphs, diagrams) is a prerequisite for many publication types. Submission of original and editable artwork files is encouraged. Digital photography files should have a resolution of at least 300 dpi and be at least 107 mm wide . Before and after images should be taken with the same intensity, direction, and colour of light
• In almost all cases, if you have a finished manuscript, you should submit it, rather than contacting EBioMedicine to enquire whether an unseen manuscript is likely to be accepted. Unless you have been asked by the Editor to submit by email, you should use the online system for all types of submission
• If you have any technical problems or questions, please contact our dedicated customer support:
For the Americas: +1 888 8347287 (09:00 to 17:00 central standard time)
For Asia and Pacific: +81 3 55615032 (09:30 to 17:30 Japan standard time)
For Europe and rest of the world: +44 1865 843577
(08:30 to 17:00 GMT)
For Chinese-speaking customers: +86 10 85208780
(9:00 to 17:30 China standard time)
For Spanish-speaking customers: +34 932 406176
(09:00 to 17:00 GMT)
For French-speaking customers: +33 171 165608
(09:00 to 17:00 GMT)
Email: ebiom@lancet.com
First submissions to EBioMedicine should include:
1 Covering letter
2 Manuscript including tables and panels
3 Figures
4 Author statement form (see next section)
5 Declaration of interests and source of funding statements (Conflict of Interest statement, see next section)
6 In-press papers—one copy of each with acceptance letters
7 Protocols and CONSORT details for randomised controlled trials or relevant reporting details for non-RCT studies, such as ARRIVE checklist for animal studies. Please see full list of reporting guidelines in Research papers section, below.
8 We encourage disclosure of correspondence from other journals and reviewers, if previously submitted, and we might contact relevant editors of such journals
9 Research in context panel, for all primary Research papers
Covering letter
• You should upload your covering letter at the “Enter Comments”
stage of the online submission process
• Use the covering letter to explain why your paper should be published in EBioMedicine. In the letter, please briefly describe any relevant literature to provide context for the work, as well as a summary of the main findings of the paper—with a clear indication of how the work advances the field. In particular, a brief description of how the study relates to human health, as well as the translationally-relevant insights provided by the work, can be helpful
Statements, permissions, and signatures
Authors and contributors
• Designated authors should meet all four criteria for authorship in the ICMJE Recommendations
• All authors, and all contributors (including medical writers and editors), should specify their individual contributions at the end of the main text within the manuscript (in addition to the Author statements form, below)
• We require that more than one author has verified the underlying data. The contributors statement should state who those authors are.
• We encourage collaboration and coauthorship with colleagues in the locations where the research is conducted
• The Lancet Group takes a neutral position with respect to territorial claims in institutional affiliations
• When choosing coauthors, we ask lead authors to be mindful of the benefits of diversity in authorship and to consider inviting coauthors who reflect diversity in every sense, including (but not limited to) background, career-stage, gender, geography, and race
• For author groups of more than 30 members, we encourage use of a collaborator or study group for any additional authors. For this collaborator or study group, if they wish to be indexed to the paper, please provide a separate document with a table of first names and surnames of all members of the group (this is to ensure that PubMed and similar databases encode the names correctly).
Forms and signatures
For Reviews, Commentaries, and Letters, we require you to upload your forms at submission. For original Research papers, if forms have not been included in the initial submission, we will request them after peer review. The following signed statements are a prerequisite for acceptance and publication in EBioMedicine:
• Authors’ contributions and signatures (Author statements form). EBioMedicine will not publish any paper unless we have the signatures of all authors
• Conflicts of interest statements (ICMJE forms)
• Statements of role, if any, of medical writer or editor
• Acknowledgments—written consent of cited individual
• Personal communications—written consent of cited individual
• Use of copyright-protected material—signed permission statements from author and publisher
These statements can be scanned and submitted electronically with your submission. Please note that The Lancet journals will accept hand-signed and electronic (typewritten) signatures.
Declaration of interests
A conflict of interest exists when professional judgement concerning a primary interest (such as patients’ welfare or validity of research) may be influenced by a secondary interest (such as financial gain). Financial relationships are easily identifiable, but conflicts can also occur because of personal relationships or rivalries, academic competition, or intellectual beliefs. A conflict can be actual or potential, and full disclosure to the Editor of all relationships is a requisite. Purposeful failure to disclose conflicts is a form of misconduct and might lead to publication of a correction or even to retraction. All submissions to EBioMedicine must include disclosure of all relationships in which there is a potential or actual conflict of interest, even if it not directly relevant to the submitted work. The Editor may use such information as a basis for editorial decisions and will publish all disclosures that authors declare on their conflict of interests form. Agreements between authors and study sponsors that interfere with authors’ access to all of a study’s data, or that interfere with their ability to analyse and interpret the data and to prepare and publish manuscripts independently, may represent conflicts of interest, and should be avoided. Authors may be required to provide the journal with any such agreements in confidence.
• At the end of the text, under a subheading “Declaration of interests”, all authors must disclose any financial and personal relationships with other people or organisations, even if it does not directly relate to the submitted work. Examples of financial conflicts include employment, consultancies, stock ownership, honoraria, paid expert testimony, patents or patent applications, and travel grants, all within 3 years of beginning the work submitted. If there are no conflicts of interest, authors should state that none exist
• All authors are required to provide a Conflict of Interest Statement and should complete a standard form, which is available at https://www.thelancet.com/for-authors/forms?section=icmje-coi. The form has been modified by the ICMJE following consultation with authors and editors. Further information is available in a joint ICMJE statement published on July 1, 2010. For more information see Lancet 2009; 374: 1395–96.
• For Commentaries and Reviews, EBioMedicine will not publish if an author, within the past 3 years, and with a relevant company or competitor, has any stocks or shares, equity, a contract of employment, or a named position on a company board; or has been asked by any organisation other than EBioMedicine to write, be named on, or to submit the paper (see Lancet 2004; 363: 2–3)
• For any Review, the use of medical writers is not permitted unless they have been paid and instructed directly by an author, or their institution, and their role is purely technical (eg, editing a first draft for language and grammar). If you are contemplating use of a medical writer, please contact the journal immediately to ensure it complies with our policies
Role of the funding source
• All sources of funding should be declared as an
acknowledgment at the end of the text
• At the end of the Methods section, under a subheading “Role of the funding source”, authors must describe the role of the study sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication
• If there is no Methods section, the role of the funding source should be stated as an acknowledgment. If the funding source had no such involvement, the authors should so state
• All authors should confirm that they had full access to all the data in the study and accept responsibility to submit for publication
Role of medical writer or editor
• If a medical writer or editor was involved in the creation of your manuscript, we need a signed statement from the corresponding author to include their name and information about funding of this person
• This information should be added to the Acknowledgments or Contributors section
• We require signed statements from any medical writers or editors declaring that they have given permission to be named as an author, as a contributor, or in the Acknowledgments section
……
